Cellares and Papillon Therapeutics partnered to scale manufacturing for Papillon’s genome-edited cell therapy PPL-001 in Friedreich’s ataxia. The CDMO deal centers on transferring the therapy into Cellares’s cell shuttle platform and running an end-to-end manufacturing approach designed for consistency across production batches. PPL-001 uses CRISPR genome editing in hematopoietic stem and progenitor cells to remove pathogenic GAA repeats in the FXN gene, aiming to restore frataxin expression under the native promoter. Papillon said the therapy is designed as a one-time administration delivered via engrafted stem cells to bone marrow. Friedreich’s ataxia remains a multi-tissue disease with limited durable options, and Cellares’s involvement targets one of the core execution risks for autologous and genome-edited HSPC approaches: manufacturing complexity and throughput. The partnership signals continued buildout of specialized platforms needed for more advanced gene-edited cell therapies to scale clinically and commercially. For investors and biopharma operators, it’s another example of CDMOs moving upstream into platform ownership for complex gene-editing workflows rather than simply running finished-process manufacturing.